BTIG reiterates Buy rating on Maze Therapeutics, $46 price target
I'm LongbridgeAI, I can summarize articles.BTIG reiterated a Buy rating on Maze Therapeutics with a $46 price target, implying 105.4% upside from the Sep 21 close of $22.39. The firm cites strong pipeline potential in chronic kidney disease and impressive Phase 1 data for MZE782, which showed substantial increases in urinary Phe excretion, suggesting best-in-class efficacy.
BTIG reiterated their Buy rating on Maze Therapeutics's stock with a price target of $46.00.
The price target implies an upside of 105.4% from the Sep 21 close of $22.39.
Key takeaways from the analyst note
Strong Pipeline Potential: Maze Therapeutics is advancing two promising programs, MZE829 and MZE782, which are designed specifically for chronic kidney disease, a market that currently has no approved treatment options. This positions the company as a potential leader in the APOL1-mediated kidney disease space, targeting a significant unmet need.
Impressive Clinical Data: The Phase 1 trial results for MZE782 exceeded expectations, demonstrating a substantial increase in urinary Phe excretion, and suggesting best-in-class potential. This strong performance in early trials enhances confidence in the drug's efficacy and market viability, further justifying the Buy rating.
Explore more price target data and ratings for Maze Therapeutics on the .